Introduction Neurocrine Biosciences is a pharmaceutical company that focuses on developing drugs to treat neurological and endocrine-related diseases and disorders. The company's research and development efforts include Elagolix for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other conditions. Neurocrine Biosciences has several products in various stages of clinical trials, including CRF1 Antagonist for mood disorders and Cardiovascular related diseases, CRF2 Peptide Agonist, and Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia. The company has partnerships with GlaxoSmithKline and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize certain drugs. Neurocrine Biosciences was established in 1992 and is headquartered in San Diego, California. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 23 |
AAV based gene therapy | 1 |
Target |
Mechanism GnRHR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date23 Jul 2018 |
Target |
Mechanism VMAT2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date11 Apr 2017 |
Target |
Mechanism COMT inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date24 Jun 2016 |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Sep 2024 |
Sponsor / Collaborator Yale University [+1] |
Start Date24 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Hydrocortisone ( GR ) | Adrenal Hyperplasia, Congenital More | Approved |
Valbenazine Tosylate ( VMAT2 ) | Tardive Dyskinesia More | Approved |
Crinecerfont ( CRHR1 ) | Adrenal Hyperplasia, Congenital More | NDA/BLA |
DNL-0200 | Adrenal Hyperplasia, Congenital More | Phase 3 |
Osavampator ( AMPA receptor ) | Depressive Disorder, Major More | Phase 2 |